CNS Pharmaceuticals Inc expected to post a loss of 11  cents a share - Earnings Preview

CNS Pharmaceuticals

10/05/2022 13:02

* CNS Pharmaceuticals Inc  CNSP.OQ   CNSP.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * ​Refinitiv's mean analyst estimate for CNS Pharmaceuticals
Inc
is for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of 15 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months. ​
    * Wall Street's median 12-month price target for CNS
Pharmaceuticals Inc is $4​, above​ its last closing price
of $0.30. ​​​

This summary was machine generated May 10 at 12:02 GMT.  All
figures in US dollars  unless otherwise stated